DYNAMICS OF QUALITY OF LIFE INDICATORS IN PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT AND METHOD OF THEIR CORRECTION
DOI:
https://doi.org/10.32782/2226-2008-2025-3-8Keywords:
chronic hepatitis C, quality of lifeAbstract
In addressing the issue of treatment of patients with chronic hepatitis C (CHC), scientists publish new data and discover new opportunities every day. The modern view of etiotropic therapy for patients with CHC has changed the approach to treatment. Therefore, today the effectiveness of direct antiviral drugs has been proven, which lead to the elimination of the virus, leaving unresolved the issues of further progression of liver fibrosis and improvement of quality of life.The aim of the study was to evaluate the degree of liver fibrosis and quality of life in patients with CHC when using drugs with direct antiviral action and the method of their correction.Materials and methods. We examined 66 patients with HCV with pre-existing grade 1 and 2 liver fibrosis before treatment. 33 patients of group 1 received etiotropic therapy with direct-acting antiviral drugs – sofosbuvir and ledipasvir, 33 patients of group II received additional methadoxine as pathogenetic treatment. The diagnosis was confirmed by polymerase chain reaction and enzyme-linked immunosorbent assay.Quality of life was assessed using the SF-36 scale.Results. A decrease in quality indicators was observed in all patients with CHC in the form of complaints of general weakness, increased fatigue, decreased performance, mood depression, irritability, pain or heaviness in the right hypochondrium, abdominal bloating, bleeding gums, and joint pain. The greatest impairment was found in the psychological component of quality of life due to indicators of role functioning and general health of patients. Methadoxine can be recommended in the treatment of patients with CHC as a means of pathogenetic therapy, the use of which leads to a decrease in the severity of liver fibrosis and improvement of quality of life.
References
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018; 69(2): 461–511. doi: 10.1016/j.jhep.2018.03.026.
Farrag Ahmed N, Kamel Ahmed M. Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis. Virol J. 2024; 21(1): 275. doi: 10.1186/s12985-024-02544-2.
Hladkykh FV, Liadova TI. Characteristics of the hepatotropic activity of cell-free cryopreserved biological agents in the model of autoimmune hepatitis. Journal of V.N. Karazin Kharkiv National University. Series Medicine. 2024; 32(3): 275–289. https://doi.org/10.26565/2313-6693-2024-50-01.
Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, Lucenteforte E. Efficacy and safety of DAA in children and adoles- cents with chronic HCV infection: A systematic review and meta-analysis. Liver Int. 2024; 44(3): 663–681. doi: 10.1111/ liv.15827.
Malte H. Wehmeyer, Ingiliz P, Christensen S, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). Journal of medical virology. 2018; 90(2): 304–312. https://doi.org/10.1002/jmv.24903.
Medical care standards “Viral hepatitis C in adults”. Order of the Ministry of Health of Ukraine No. 51, January 15, 2021. Available from: https://zakon.rada.gov.ua/rada/show/v0051282-21#n11.
Moskalyuk VD, Rudan IV. Сomparison of the efficiency of different treatment schemes for patients with chronic hepatitis С with and without HIV-infection. Infectious diseases. 2022; 2(108): 32–38. Available from: http://dx.doi.org/ 10.11603/1681-2727.2022.2.13187.
Riabokon EV, Kalashnik KV, Lyadska EV, Ipatova DP, Riabokon YuYu. Effectiveness of double antiviral therapy and dynamics of life quality indicators in patients with chronic hepatitis С, depending on the response to treatment. Gepatology. 2017; 1: 22–31. https://journals.indexcopernicus.com/api/file/viewByFileId/245948.
Riabokon OV, Liadska OV, Ipatova DP, Riabokon YuYu. Efficiency and dynamic antiviral therapy and indicators of quality of life in patients with chronic hepatitis C depending on availability mixed cryoglobulin. Infectious diseases. 2016; 4(86): S30–35. doi.org/10.11603/1681-2727.2016.4.7209.
Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J Hepatol. 2021; 74(6): 1472–1482. doi: 10.1016/j.jhep.2021.03.004.
Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann. Gastroenterol. 2018; 31(5): 541–551. doi: 10.20524/aog.2018.0281.
Sumtsova K, Berezhok V, Lishnevska A, Chemych M. The dependence of changes in laboratory indicators on accom- panying pathology in patients with viral hepatitis C. Eastern Ukrainian Medical Journal. 2024; 12(1): 69–80. https://doi.org/10.21272/eumj.2024;12(1):69-80.
